170 related articles for article (PubMed ID: 16542460)
21. Appropriateness of empirical antibiotic prescription for bloodstream infections in an emergency department from 2006 to 2018: impact of the spread of ESBL-producing Enterobacterales.
Clemenceau M; Ahmed-Elie S; Vilfaillot A; Chocron R; Compain F; Lebeaux D; Grohs P
Eur J Clin Microbiol Infect Dis; 2022 Jan; 41(1):71-77. PubMed ID: 34553311
[TBL] [Abstract][Full Text] [Related]
22. Health and economic outcomes of the detection of Klebsiella pneumoniae-produced extended-spectrum beta-lactamase (ESBL) in a hospital with high prevalence of this infection.
Marra AR; Pereira CA; Castelo A; do Carmo Filho JR; Cal RG; Sader HS; Wey SB
Int J Infect Dis; 2006 Jan; 10(1):56-60. PubMed ID: 16326126
[TBL] [Abstract][Full Text] [Related]
23. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome.
Kim YK; Pai H; Lee HJ; Park SE; Choi EH; Kim J; Kim JH; Kim EC
Antimicrob Agents Chemother; 2002 May; 46(5):1481-91. PubMed ID: 11959586
[TBL] [Abstract][Full Text] [Related]
24. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
[TBL] [Abstract][Full Text] [Related]
25. Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.
Rodríguez-Baño J; Navarro MD; Romero L; Muniain MA; de Cueto M; Ríos MJ; Hernández JR; Pascual A
Clin Infect Dis; 2006 Dec; 43(11):1407-14. PubMed ID: 17083012
[TBL] [Abstract][Full Text] [Related]
26. Beta-lactam resistance mechanisms in Pseudomonas aeruginosa strains causing bloodstream infections: comparative results between Brazilian and American isolates.
Fehlberg LC; Xavier DE; Peraro PP; Marra AR; Edmond MB; Gales AC
Microb Drug Resist; 2012 Aug; 18(4):402-7. PubMed ID: 22455540
[TBL] [Abstract][Full Text] [Related]
27. Molecular detection of bla
Son TV; Manh ND; Trung NT; Quyen DT; Meyer CG; Phuong NTK; Hoan PQ; Sang VV; Nurjadi D; Velavan TP; Bang MH; Song LH
Ann Clin Microbiol Antimicrob; 2021 Sep; 20(1):60. PubMed ID: 34481499
[TBL] [Abstract][Full Text] [Related]
28. Diversity of β-lactamases produced by imipenem resistant, Pseudomonas aeruginosa isolates from the bloodstream.
Najar Peerayeh S; Pirhajati Mahabadi R; Pakbaten Toupkanlou S; Siadat SD
Burns; 2014 Nov; 40(7):1360-4. PubMed ID: 24513132
[TBL] [Abstract][Full Text] [Related]
29. Ceftolozane-tazobactam and ceftazidime-avibactam activity against β-lactam-resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Enterobacterales clinical isolates from U.S. medical centres.
Hirsch EB; Brigman HV; Zucchi PC; Chen A; Anderson JC; Eliopoulos GM; Cheung N; Gilbertsen A; Hunter RC; Emery CL; Bias TE
J Glob Antimicrob Resist; 2020 Sep; 22():689-694. PubMed ID: 32353524
[TBL] [Abstract][Full Text] [Related]
30. CTX-M-15 and OXA-10 beta lactamases in multi drug resistant Pseudomonas aeruginosa: First report from Pakistan.
Ullah W; Qasim M; Rahman H; Khan S; Rehman ZU; Ali N; Muhammad N
Microb Pathog; 2017 Apr; 105():240-244. PubMed ID: 28258003
[TBL] [Abstract][Full Text] [Related]
31. Pseudomonas aeruginosa bacteraemia in patients with hematologic malignancies: risk factors, treatment and outcome.
Tofas P; Samarkos M; Piperaki ET; Kosmidis C; Triantafyllopoulou ID; Kotsopoulou M; Pantazatou A; Perlorentzou S; Poulli A; Vagia M; Daikos GL
Diagn Microbiol Infect Dis; 2017 Aug; 88(4):335-341. PubMed ID: 28529091
[TBL] [Abstract][Full Text] [Related]
32. Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β-lactamase-producing Enterobacteriaceae.
Russo A; Falcone M; Gutiérrez-Gutiérrez B; Calbo E; Almirante B; Viale PL; Oliver A; Ruiz-Garbajosa P; Gasch O; Gozalo M; Pitout J; Akova M; Peña C; Cisneros JM; Hernández-Torres A; Farcomeni A; Prim N; Origüen J; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Karaiskos I; de la Calle C; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Mora-Rillo M; Rodriguez-Gomez J; Souli M; Bonomo RA; Paterson DL; Carmeli Y; Pascual A; Rodríguez-Baño J; Venditti M;
Int J Antimicrob Agents; 2018 Nov; 52(5):577-585. PubMed ID: 29969692
[TBL] [Abstract][Full Text] [Related]
33. Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study).
Bergas A; Albasanz-Puig A; Fernández-Cruz A; Machado M; Novo A; van Duin D; Garcia-Vidal C; Hakki M; Ruiz-Camps I; Del Pozo JL; Oltolini C; DeVoe C; Drgona L; Gasch O; Mikulska M; Martín-Dávila P; Peghin M; Vázquez L; Laporte-Amargós J; Durà-Miralles X; Pallarès N; González-Barca E; Álvarez-Uría A; Puerta-Alcalde P; Aguilar-Company J; Carmona-Torre F; Clerici TD; Doernberg SB; Petrikova L; Capilla S; Magnasco L; Fortún J; Castaldo N; Carratalà J; Gudiol C
Microbiol Spectr; 2022 Jun; 10(3):e0229221. PubMed ID: 35475683
[TBL] [Abstract][Full Text] [Related]
34. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
Juan C; Zamorano L; Pérez JL; Ge Y; Oliver A; ;
Antimicrob Agents Chemother; 2010 Feb; 54(2):846-51. PubMed ID: 19933793
[TBL] [Abstract][Full Text] [Related]
35. Risk Factors and Outcomes of Antibiotic-resistant Pseudomonas aeruginosa Bloodstream Infection in Adult Patients With Acute Leukemia.
Zhao Y; Lin Q; Liu L; Ma R; Chen J; Shen Y; Zhu G; Jiang E; Mi Y; Han M; Wang J; Feng S
Clin Infect Dis; 2020 Dec; 71(Suppl 4):S386-S393. PubMed ID: 33367574
[TBL] [Abstract][Full Text] [Related]
36. Detection of Pseudomonas aeruginosa isolates carrying the bla
Liu CP; Chen TL; Wang NY; Chow SF; Lin JC; Yan TR
J Microbiol Immunol Infect; 2017 Feb; 50(1):68-74. PubMed ID: 25648667
[TBL] [Abstract][Full Text] [Related]
37. Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in
Poirel L; Ortiz De La Rosa JM; Kieffer N; Dubois V; Jayol A; Nordmann P
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323045
[TBL] [Abstract][Full Text] [Related]
38. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
Ciofu O
APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
[TBL] [Abstract][Full Text] [Related]
39. Bloodstream infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: epidemiology, microbiology, and clinical outcomes.
Marra AR; Pereira CA; Gales AC; Menezes LC; Cal RG; de Souza JM; Edmond MB; Faro C; Wey SB
Antimicrob Agents Chemother; 2006 Jan; 50(1):388-90. PubMed ID: 16377720
[TBL] [Abstract][Full Text] [Related]
40. Bloodstream infection due to extended-spectrum beta-lactamase (ESBL)-positive K. pneumoniae and E. coli: an analysis of the disease burden in a large cohort.
Leistner R; Gürntke S; Sakellariou C; Denkel LA; Bloch A; Gastmeier P; Schwab F
Infection; 2014 Dec; 42(6):991-7. PubMed ID: 25100555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
